RSMDF:OTO-Resmed Inc Ord (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 17.7

Change

0.00 (0.00)%

Market Cap

USD 10.10B

Volume

N/A

Analyst Target

USD 11.49
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 68.29B
ALC Alcon AG

N/A

USD 43.81B
HYB New America High Income Closed..

N/A

USD 35.93B
RMD ResMed Inc

N/A

USD 31.27B
WST West Pharmaceutical Services I..

N/A

USD 26.66B
BAX Baxter International Inc

N/A

USD 17.96B
ATR AptarGroup Inc

N/A

USD 9.79B
TFX Teleflex Incorporated

N/A

USD 9.61B
STVN Stevanato Group SpA

N/A

USD 5.95B
BLCO Bausch + Lomb Corp

N/A

USD 5.15B

ETFs Containing RSMDF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.02% 79% B- 76% C+
Dividend Return 0.59% 56% F 32% F
Total Return 9.62% 84% B 75% C
Trailing 12 Months  
Capital Gain -18.43% 32% F 12% F
Dividend Return 0.88% 44% F 9% A-
Total Return -17.55% 26% F 11% F
Trailing 5 Years  
Capital Gain 68.89% 75% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.89% 75% C 75% C
Average Annual (5 Year Horizon)  
Capital Gain 14.72% 62% D 62% D
Dividend Return 15.51% 59% D- 59% D-
Total Return 0.79% 47% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 73.12% 35% F 39% F
Risk Adjusted Return 21.21% 60% D- 56% F
Market Capitalization 10.10B 84% B 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.